Druckenmiller's Duquesne Family Office previously initiated a position in Revolution Medicines in the first quarter of 2026. Although Wall Street analysts only expect the biotech company's stock price to rise by about 7% in the next 12 months, Druckenmiller is optimistic about its product pipeline, especially daraxonrasib, a drug for metastatic pancreatic cancer that is currently seeking US FDA and European approval, and is expected to generate annual sales of $5 billion to $7.6 billion.